论文部分内容阅读
目的:分析艾塞那肽对新诊断2型糖尿病患者生化指标及骨代谢的影响。方法:选取2013年1月-2014年12月在我院就诊的2型糖尿病患者40人进行基本生化指标的检查后,皮下注射艾塞那肽进行治疗24周后,测定生化指标,比较治疗前后各项指标的变化情况及患者腰椎的骨密度。结果:与治疗前相比,治疗24周后,患者的空腹血糖值(FPG)、糖化血红蛋白(Hb A1c)、总脂肪率显著降低,差异具有统计学意义(P<0.01);胰岛素抵抗指数(HOMA-IR)、体重、身体质量指数(BMI)值及脂肪指数(FMI)值显著降低,差异统计学意义(P<0.05);胰岛素功能指数(HOMA-β)、骨钙蛋白(OC)、环磷酰胺(CTX)、抗酒石酸5b(TRAc P5b)、骨密度(BMD)值与治疗前相比,差异无统计学意义(P>0.05)。结论:使用艾塞那肽治疗2型糖尿病患者的血糖值和机体对胰岛素抵抗作用得到良好的改善,但患者的骨密度及骨转化物标志物等并无明显变化。
OBJECTIVE: To analyze the effect of exenatide on biochemical markers and bone metabolism in newly diagnosed type 2 diabetic patients. Methods: Forty patients with type 2 diabetes mellitus who were treated in our hospital from January 2013 to December 2014 were selected for basic biochemical tests. After exenatide was injected subcutaneously for 24 weeks, the biochemical indexes were compared. Before and after treatment Changes in various indicators and patients with lumbar spine bone mineral density. Results: After treatment for 24 weeks, the fasting blood glucose (FPG), Hb A1c, and total fat in patients were significantly lower than those before treatment, the difference was statistically significant (P <0.01); the insulin resistance index HOMA-IR, body mass index, body mass index (BMI) and fat index (FMI) were significantly decreased The levels of CTX, TRAc P5b and BMD were not significantly different from those before treatment (P> 0.05). CONCLUSIONS: Exenatide treatment of type 2 diabetes patients with blood glucose levels and the role of the body to insulin resistance improved well, but the patient’s bone mineral density and bone turnover markers did not change significantly.